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Tumor suppressor candidate 5 (TUSC5) is a gene expressed abundantly in white adipose tissue (WAT), brown adipose tissue
(BAT), and peripheral aﬀerent neurons. Strong adipocyte expression and increased expression following peroxisome proliferator
activated receptor γ (PPARγ) agonist treatment of 3T3-L1 adipocytes suggested a role for Tusc5 in fat cell proliferation and/or
metabolism. However, the regulation of Tusc5 in WAT and its potential association with obesity phenotypes remain unclear.
We tested the hypothesis that the TUSC5 gene is a bona ﬁde PPARγ target and evaluated whether its WAT expression or
single-nucleotide polymorphisms (SNPs) in the TUSC5 coding region are associated with human obesity. Induction of Tusc5
mRNA levels in 3T3-L1 adipocytes by troglitazone and GW1929 followed a dose-response consistent with these agents’ binding
aﬃnities for PPARγ. Chromatin immunoprecipitation (ChIP) experiments conﬁrmed that PPARγ protein binds a ∼− 1.1kb
promotor sequence of murine TUSC5 transiently during 3T3-L1 adipogenesis, concurrent with histone H3 acetylation. No
change in Tusc5 mRNA or protein levels was evident in type 2 diabetic patients treated with pioglitazone. Tusc5 expression
was not induced appreciably in liver preparations overexpressing PPARs, suggesting that tissue-speciﬁc factors regulate PPARγ
responsiveness of the TUSC5 gene. Finally, we observed no diﬀerences in Tusc5 WAT expression or prevalence of coding region
SNPs in lean versus obese human subjects. These studies ﬁrmly establish the murine TUSC5 gene locus as a PPARγ target,
but the signiﬁcance of Tusc5 in obesity phenotypes or in the pharmacologic actions of PPARγ agonists in humans remains
equivocal.
Copyright © 2009 Trina A. Knotts et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.2 PPAR Research
1.Introduction
Tumor suppressor candidate 5 (TUSC5, also known as
LOST1 or BEC-1) was originally identiﬁed as a gene locus
disrupted in some lung cancers and, therefore, hypothesized
to participate in attenuation of cancer cell proliferation [1].
Consistent with this postulate, Tusc5 protein contains a
CD225 interferon-induced transmembrane protein domain
[2], found in the archetypal interferon-responsive 9–27
protein that is implicated in antiproliferative actions of
interferons [3]. It is now ﬁrmly established that Tusc5
expression is remarkably tissue speciﬁc in rodents and
humans, with robust expression in mature white and brown
adipocytes [2, 4, 5] and in peripheral aﬀerent neurons
[2]. This unique expression pattern suggests an important
function for Tusc5 in both adipose tissue and the peripheral
nervous system.
With respect to fat tissue, we proposed a working
hypothesis in which Tusc5 participates in pathways modu-
lating adipocyte proliferation or promoting cell cycle growth
arrest/fat cell maturation in response to environmental or
centralnervoussystemcues[2].Thismodelwasbasedlargely
on the putative tumor suppressor features of Tusc5 (see
above), coincident expression of Tusc5 with adipocyte mark-
ers that increase as 3T3-L1 adipocytes exit the mitotic clonal
expansion phase to terminally diﬀerentiate and mature [2],
and the repression of Tusc5 expression in the “proliferative”
brown adipose tissue (BAT) of cold exposed rodents ([4];
alsosee[2]).Accordingtothismodel,Tusc5hasa“governor”
role that would be dampened when adipocyte growth cues
are triggered (i.e., by cold or obesity). However, the exact
physiological function of Tusc5 has remained elusive.
Despite recent advancements in the characterization of
Tusc5 biology in fat cells, its gene regulators and potential
linkstoobesityphenotypesremaintobeclariﬁed.Identifying
factors that inﬂuence Tusc5 gene expression and gaining
a better understanding of associations between the TUSC5
gene sequence, expression patterns, and obesity will enable
a deeper understanding of its physiological function. Previ-
ously, we reported that Tusc5 mRNA and protein abundance
increase following short-term (∼1d a y )o r1 - w e e kt r e a t m e n t
of 3T3-L1 adipocytes with a high concentration of the
peroxisomeproliferatoractivatedreceptorγ(PPARγ)agonist
GW1929 [2], supporting the hypothesis that TUSC5 is a
bonaﬁdePPARγ targetgene.Ifconﬁrmed,thiswouldbolster
the view that Tusc5 is a metabolically-relevant factor, since
PPARγ target genes typically participate in adipocyte func-
tion and other important metabolic processes. To address
this question further, we searched for potential PPARγ-
response elements (DR1 sites) in the murine TUSC5 pro-
moter, performed chromatin immunoprecipitation (ChIP)
studies to determine whether PPARγ interacts with these
sites during 3T3-L1 adipogenesis, and assessed whether
these interactions take place concurrent with changes in
chromosomal histone acetylation. To gain insight into
the clinical relevance of PPARγ-TUSC5 interactions, Tusc5
mRNAlevelswerecomparedinarchivedhumanWATbiopsy
samples before and after treatment with the PPARγ agonist
pioglitazone or rosiglitazone. In a complementary line of
research, we examined relationships between obesity and
Tusc5, by comparing TUSC5 gene coding variants and its
WAT mRNA expression in obese and nonobese human
subjects. We hypothesized that WAT Tusc5 transcript levels
would be reduced during states characterized by white
adipocyte proliferation, as in obesity, and that the frequency
of sequence variation in the TUSC5 coding region would
diﬀerbetweenleanversusobesehumans.Ourresultssupport
the view that murine TUSC5 is a PPARγ target gene, but
a relationship between Tusc5, obesity, and pharmacological
actions of PPARγ agonists remains equivocal.
2. Methods
Materials. Insulin, dexamethasone,3-isobutyl-1-methylxan-
thine (IBMX), and GW1929 were purchased from Sigma.
DMEM and Superscript III First-strand synthesis kit were
purchased from Invitrogen. Tissue culture dishes and mul-
tiwell plates were from BD Falcon. Newborn calf serum was
obtained from Hyclone and lot-tested fetal bovine serum
(FBS) was purchased from Atlas Biologicals.
2.1. Experiments to Evaluate the Tusc5 Gene Locus as
aP P A R γ Target
3T3-L1 Adipocyte Diﬀerentiation and PPARγ Agonist Dose-
Response Studies. The impact of treatment with GW1929
and troglitazone on Tusc5 mRNA abundance was tested
in the murine 3T3-L1 adipocyte model. Cells were grown
as described previously [2], except insulin was withdrawn
after the initial two-day diﬀerentiation period and cells were
grown in 6-well uncoated plates. Mature adipocytes (10–
12 days postdiﬀerentiation, media changed every 3-4 days)
were grown for 18 hours in media containing the potent
non-thiazolidinedione PPARγ agonist GW1929 [6] or the
less potent thiazolidinedione (TZD) agonist troglitazone in
order to generate a dose-response relationship of Tusc5
expression (n = 4/per dose); controls were grown in
media containing dimethyl sulfoxide vehicle (DMSO; 0.1%
by vol.). The experiment was replicated twice. RNA was
prepared using Trizol-based methods for cell culture samples
as per manufacturer’s instructions (Ambion, Austin, TX),
and transcript abundances of target genes were measured
as described under “Gene Expression Analyses” Section
below. Parallel-treated plates were used to generate protein
lysates for measurement of Tusc5 protein by Western blot, as
described below.
Chromatin Immunoprecipitation (ChIP) Assays. ChIP assays
were performed as described previously [7]. In brief,
conﬂuent preadipocytes (day 0) and diﬀerentiated 3T3-
L1 adipocytes (at day 4 or 8 following addition of diﬀer-
entiation cocktail, which was added over days 1-2) were
cross-linked in 1% formaldehyde at 37◦Cf o r1 0m i n u t e s
and resuspended in 200μL of Nonidet P-40-containing
buﬀer (5mM PIPES, pH 8.0, 85mM KCl, and 0.5%
NP-40). Crude nuclei were isolated and lysed in 200μLPPAR Research 3
lysis buﬀer (1% SDS, 10mM EDTA and 50mM Tris-
HCl, pH 8.1), and lysates were sonicated and diluted 10-
fold with immunoprecipitation buﬀer (16.7mM Tris-HCl
[pH 8.1], 167mM NaCl, 1.2mM EDTA, 0.01% SDS, and
1.1% Triton X-100). Lysates were immunoprecipitated with
antiacetylated-histoneH3(K9)(1μg),antiacetylated-histone
H4 (pan)(1μg), or antiPPARγ (1μg) antibodies for 12 hours
at 4◦C. Immune complexes were incubated with Protein A-
Sepharose CL-4B (Amersham-Biosciences) for 2 hours at
4◦C. “Input” represents 10% of the total input chromatin.
After successive washings, immune complexes containing
DNA were eluted and the precipitated DNA was ampliﬁed
by PCR. These experiments were replicated three times.
Promoter primer pairs used in this study are as follows: (1)
301bp amplicon for putative −8kb DR -1 (5  : GTTCCA-
CATATGTTGAACT, 3 : GAAGGAAGAAAGACAGACT); (2)
289bp amplicon for putative −1.8kb DR-1 (5 : CACCAAG-
CAAACATGCTTT, 3 : ACAACATGCACGTAAGTGC); (3)
304bp amplicon for putative −1.1kb DR-1 (5 : AAAGC-
CACCCTTCCCATAC; 3 : CCTAAAGCCACCAAGGGAA);
(4) nonspeciﬁc 374bp amplicon near the putative −8kb
DR-1 sequence (5 : AGTCTGTCTTTCTTCCTTC, 3 :T G C -
TACAAGAAACCTTTCA). Antibodies against acetylated-
histone H3 (K9), acetylated-histone H4 (pan) were pur-
chasedfromUpstateBiotechnology,andtheantibodyagainst
PPARγ was from Abcam.
Tusc5 WAT Transcript Abundance Following Treatment with
TZDs in Subjects with Type 2 Diabetes Mellitus (T2DM). In
the ﬁrst study, archived samples were available from a subset
of volunteers involved in a study previously described [8].
Subjects with T2DM were treated with pioglitazone (PIO)
(30mg/day; n = 16: 5 male, 11 female) or placebo (n = 16:
7 male, 9 female) for 11–17 weeks. If fasting plasma glucose
was>100mg/dL orHbA1c was ≥7.0% atweek 8of thestudy,
the dose of PIO was increased to 45mg/d. Subcutaneous
abdominal adipose tissue (WAT) biopsies were obtained by
Bergstrom needle at the beginning and end of the study
after an overnight fast, with local Lidocaine anesthesia,
and samples were ﬂash frozen and stored at −80◦C until
processed for mRNA and target gene transcript quantitation
as described below. Clinical studies were approved by the
Institutional Review Board of the Pennington Biomedical
Research Center.
In a second line of research, archival tissue samples were
from 27 type 2 diabetic subjects, participants in studies
where the objectives were to generate expression proﬁles
before and after TZD treatment. Some reports from the
individual clinical studies have been published previously
[9, 10]. The subjects are a subset of a larger, three-study
cohort used to study expression proﬁles related to insulin
resistance and TZD treatment [11]. The pioglitazone study
included eight subjects (all male, age 48 ± 3y e a r s ,B M I
36.5 ± 2.8kg/m 2, fasting plasma glucose 173 ± 19mg/dL).
The rosiglitazone study included 19 subjects (6 female/13
male, age 52 ± 2y e a r s ,B M I3 5 .6 ± 1.4kg/m 2, fasting plasma
glucose 183 ± 15mg/dL). Needle biopsies of abdominal
subcutaneous adipose tissue were harvested before and
after 12-week treatment with pioglitazone (45mg/day) or
rosiglitazone (8mg/day). Biopsies were ﬂash frozen in liquid
nitrogen and stored at −80◦C. Oligonucleotide microarrays
(Human Genome U133 Plus 2.0, Aﬀymetrix, Inc., Santa
Clara, CA) were used to generate gene expression proﬁles
from each adipose tissue sample. RNA preparation and array
analyses have been described [11]. Gene expression levels,
expressedasaveragediﬀerencescores,weredeterminedusing
Aﬀymetrix MAS 5.0 software. The experimental protocols
were approved by the Institutional Review Board for Human
Subjects of the University of California, San Diego, and
informed written consent was obtained from each subject.
2.2. Studies of Tusc5 Gene Activation by PPARγ Outside
the Context of Adipocytes
Analyses of Tusc5 Gene Expression in Livers of Mice Over-
expressing PPARγ1 or PPARγ2 in Liver. For examination
of the eﬀect of liver PPARγ1 overexpression on expression
of Tusc5, samples were used from a previously published
study in which PPARα knockout mice were treated with i.v.
doses of adenovirus preparations containing either murine
PPARγ1( n = 3) or LacZ control (n = 3) over expression
contructs that drive expression primarily in liver (see [12]
for details related to animal treatments and RNA isolation).
Total RNA was subjected to quantitative PCR using Taqman
primers and probes directed against Tusc5 or the positive
control PPARγ target gene adipoQ (encoding adiponectin),
as described below.
For determination of the eﬀects of liver overexpression
of murine PPARγ2 on hepatic expression of Tusc5, archived
samples were used from a previously published experiment
in which C57BL/6 mice were i.v. treated with adenovirus
preparations containing either murine PPARγ2( n = 6) or
LacZ (control, n = 7) overexpression constructs [13]. cDNA
from total RNA (oligo −dT primed) was prepared from
liver tissue, and gene expression analyses were performed as
described below.
Eﬀects of Overexpression of PPAR isoforms in HepG2 Hep-
atoblastoma Cells. These studies were conducted at Osaka
University, and the tightly tetracycline (tet)-regulatable
HepG2-tet-oﬀ-hPPAR (PPAR isoforms α, β/δ, γ1, γ2)
hepatoblastoma cells used in these experiments, cell cul-
ture conditions, and RNA preparation techniques have
been described elsewhere in detail [14]. Brieﬂy, cells were
cultured in Dulbecco’s Modiﬁed Eagle’s Medium (high
glucose DMEM) containing 10% heat-inactivated FBS,
100IU/mL penicillin, 100μg/mL streptomycin, 300μg/mL
G418 antibiotic, 0.5μg/mL puromycin, and 2μg/mL Tet. For
PPAR ligand treatments, cells were cultured in the medium
supplemented with 10% heat-inactivated charcoal/dextran-
treated FBS. To overexpress the PPAR isoforms, HepG2-tet-
oﬀ-hPPAR cells (7 × 105 cells/dish) were seeded in 6cm
dishes without Tet for 24 hours [14]. Cells were then
treatedwithPPARligand(1μMGW7647forPPARα,100nM
GW501516 for PPARδ,o r1 μM rosiglitazone for PPARγ)
or vehicle (0.1% DMSO) for 24 hours. Total RNA was4 PPAR Research
isolated from the cells using the QuickGene RNA cultured
cell HC kit (FUJIFILM) according to the manufacturer’s
instructions. mRNA prepared from these samples was trans-
ferred to the WHNRC for quantitative PCR analyses, as
described below. RNA was quantiﬁed on a NanoDrop ND-
1000 spectrophotometer and processed as described below
for measurement of transcript abundances of target genes
including human Tusc5 and the positive control pan-PPAR-
target gene adipose diﬀerentiation related protein (ADRP
or ADFP) plus the PPAR targets phosphoenolypyruvate 1
(PEPCK1/Pck1),acyl-CoAoxidase1(ACOX1),andcarnitine
palmitoyltransferase 1b (Cpt1b). There was a total of 3-
sample/treatment group.
2.3. Studies Evaluating Tusc5 in Human Obesity. Clinical
investigations were approved by the institutional review
boards of each participating center and were performed
according to the Declaration of Helsinki.
Expression of Tusc5 mRNA in Obese Human WAT. The
eﬀects of obesity and diﬀerences between adipose depots
with respect to Tusc5 mRNA abundance were analyzed
using archived human WAT samples from nonobese (n =
10) and obese (n = 12) subjects. Samples were derived
from female volunteers undergoing surgery, as previously
described [15]; samples are the same as those used for our
recent characterization of another adipocyte-neuron gene,
synuclein-γ (SNCG; [16]). Visceral adipose tissue (omental)
was collected in the course of laparoscopy or laparotomy
for gastroplasty or gynecological procedures, and SC fat
obtained in parallel from the abdominal region. mRNA
prepared from these samples was transferred to the WHNRC
for quantitative PCR analyses, as described below.
TUSC5SequenceVariantsinLeanandObeseSubjects. Details
regarding the subject population, exclusion and inclusion
criteria, sequencing methods, and data analysis techniques
have been previously described [17]. Genomic DNA samples
obtained from a large cohort of extremely obese (n =
381, mean BMI 49.0 ± 8.8kg/m 2) and very lean (n =
377, mean BMI 19.4 ± 1.6kg/m 2) white individuals of
European descent were analyzed at the U.S. Department of
Energy Joint Genome Institute (JGI), in the laboratory of
Dr. Len A. Pennacchio. TUSC5 (NM 172367) coding exons
and their splice sites were sequenced using gene-speciﬁc
primer sets, and sequence polymorphism allele frequencies
were compared between the lean and obese groups. Subject
recruitment was from the Ottawa community (lean subjects)
or from the University of Ottawa Weight Management Clinic
and the Heart Institute Lipid Clinic [17].
Gene Expression Analyses. RNA was prepared from 3T3-L1
adipocytesandhumanWATbiopsysamplesusingtheRibop-
ure kit (Applied Biosystems-AM1924). RNA abundance was
quantiﬁed using a NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies). cDNA was synthesized from total
RNA using Superscript III reverse transcriptase (Invitrogen)
followed by RNase-H treatment as per the manufacturer’s
instructions. Gene expression analyses by quantitative PCR
utilized gene-speciﬁc Taqman primers and FAM-MGB
labeled probes (Assays-on-Demand, Applied Biosystems,
Inc.) and were analyzed in duplicate or triplicate for each
sample using an ABI 7900HT instrument. Reactions were
carried out in a 384-well format containing the following
in each well: cDNA corresponding to 10ng of original
total RNA (3T3-L1 PPARγ dose response studies), 2ng
(PPARγ) or 10ng (Tusc5, ARBP/36B4, AdipoQ) for murine
PPARγ1a n dP P A R γ2 liver overexpression studies, 20ng
(HepG2 PPAR overexpression studies), or 5ng (human WAT
samples); cDNA was dried in each well prior to adding
qPCR reagents to facilitate an 8μL/well assay. Wells also
contained 1x Master Mix (ABI Universal PCR Master Mix
or Taqman Gene Expression Master Mix) and 1x speciﬁc
primer-probemix.Cycleconditionswere50◦Cfor2minutes,
95◦C for 10 minutes, 40 cycles of 95◦C for 15 s/60◦Cf o r1
minute. Ampliﬁcation cycle number (Ct) of control mRNA
(eukaryotic 18S) was determined using commercial primers
and probes (ABI) to correct for template loading diﬀerences,
and expression values were determined relative to treatment
control transcript levels using a mathematical formula as
previously described [2]. Primers/probe ABI identiﬁers for
mouse studies were Tusc5 (Mm00624784 m1), aP2/FABP4
(Mm00445880 m1), PPARγ (Mm00440945 m1), and ad-
iponectin/adipoQ (Mm00456425 m1). For human cell
and tissue studies, identiﬁers were ADFP (Hs00605340
m1), adiponectin/AdipoQ (Hs00605917 m1), Cpt1b (Hs
00992664 m1), PEPCK1/Pck1 (Hs00159918 m1), leptin
(Hs00174877 m1), ACOX1 (Hs00244515 m1), and LPL
(Hs00173425 m1).
Protein Extraction and Western Blot Analysis. Brieﬂy, tis-
sue samples were homogenized on ice in homogenization
buﬀer (50mM PIPES, 150mM NaCl, 1.5% n-Octyl-β-D-
glucopyranoside; 300μL/100mg tissue) with 1X HALT pro-
tease and phosphatase inhibitors (Pierce). 3T3-L1 cells were
washed once with PBS, lysed with Tusc5 homogenization
buﬀer with inhibitors, and sonicated for 5s. Lysates were
spunat20000gat4◦Cfor10minutes.Proteinconcentrations
were quantitated using the bicinchoninic acid assay (Pierce).
For Tusc5, 2.5–5μg of total protein was separated on a 12%
Bis-Tris SDS gel using 2-(N-morpholino)ethanesulfonic
(MES) acid running buﬀer (Invitrogen). The proteins
were transferred to polyvinylidene diﬂuoride membrane
and immunoblotted with rabbit anti-Tusc5 antibody (1 :
10000) in PBST overnight. Speciﬁc signal was detected with
a horseradish peroxidase-conjugated secondary antibody
(1 : 10000 goat antirabbit HRP) using Millipore Immo-
bilon Western chemiluminescent substrate (Millipore). Blots
were imaged using a Fluorochem 8800 instrument (Alpha
Innotech). Densitometry intensities fell within the linear
range as determined in pilot studies evaluating low to high
loadings of WAT lysates.
Statistics. Comparisons across more than two-treatment
groups in cell culture and molecular biology studies were
evaluated by one-way ANOVA with a posthoc Dunnett’sPPAR Research 5
test comparing groups to the control (PrismGraph 4.0,
GraphPad, San Diego, CA). For obese human WAT gene
expression results, a repeated-measures two-way ANOVA
was used to evaluate eﬀects of obesity, WAT depot, and
obesity x depot interactions: where signiﬁcant interactions
across variables were present, posthoc Bonferroni tests were
used. Unpaired t-tests were used to test for signiﬁcant diﬀer-
ences between placebo- and pioglitizone-treated groups with
respect to the change in WAT target gene transcript levels
following treatment, or when comparing agonist-treated
versus control HepG2 cells for PPAR isoform studies. For
microarray studies comparing Tusc5 WAT gene expression
in type 2 diabetics treated with TZDs, paired t-tests were
employed to compare ﬂuorescence signal values pre- versus
posttreatment. Means ± SEM are presented, and P ≤ .05 was
considered statistically signiﬁcant.
3. Results
3.1. Experiments Establishing the Murine TUSC5 Gene Locus
as a PPARγ Target. Previously, we observed in 3T3-L1
adipocytes that short-term (<24 hours) and longer-term
(7d) treatments with the non-thiazolidinedione GW1929
at a single high dose increased Tusc5 mRNA abundance
and protein [2]. To ensure that this induction is via PPARγ
activation and not oﬀ-target events speciﬁc to GW1929,
dose-response studies were conducted in mature diﬀerenti-
ated 3T3-L1 adipocytes using two diﬀerent PPARγ agonists
(GW1929 and troglitazone) that display large potency diﬀer-
ences at the level of PPARγ binding and activation (GW1929
is ∼35–66 times more potent; see [6]) and representing non-
thiazolidinedione and TZD molecule classes, respectively. As
shown in Figure 1, both agonists increased Tusc5 mRNA
abundance to over 200% of that determined in control,
vehicle-treated cells, with troglitazone having an approxi-
mately 50 times higher EC50 compared to GW1929. Also
shown are mRNA level changes for the established PPARγ
target gene, aP2, which showed identical patterns to those
seen for Tusc5. Tusc5 protein level was also increased by
agonisttreatment(SupplementaryFigure1in supplementary
material available online at doi: 10.1155/2009/86768). The
activation of Tusc5 gene expression by both agents, and the
fact that the magnitude of EC50 diﬀerences match the known
potencyofthesemoleculesforbinding andactivatingPPARγ
are consistent with the concept that Tusc5 is selectively
regulated by PPARγ agonism.
A search for potential DR1 sites (PPARγ-response ele-
ments) in the promoter region of murine TUSC5 revealed
at least three potential sites (relative to start codon,
+1) at about −1.1kb (AGGTCATAGGCCA: −1174 to
−1162), −1.8kb (AGGTCAGAGGTTG: −1840 to −1829),
and −8.4kb (AGGTCATTGGTAA: −8467 to −8455). To
determine whether PPARγ protein interacts with the TUSC5
promoter in the course of normal 3T3-L1 adipocyte dif-
ferentiation, a ChIP study focusing on binding at the DR1
sites was conducted, before diﬀerentiation (day 0) and at 4
and 8d post-initiation of adipocyte diﬀerentiation. PPARγ
protein binding at the putative DR1 site at −1.8kb was
not detected under any condition (data not shown). Strong
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Figure 1: Dose-Response of Tusc5 Gene Expression to Short-term
Treatment with PPARγ Agonists in Mature 3T3-L1 Adipocytes. (a)
Relative Tusc5 mRNA abundance in response to increasing concen-
trations of the potent and highly-selective non-thiazolidinedione
GW1929. (b) Relative Tusc5 mRNA abundance in response to
increasing concentrations of the thiazolidinedione troglitazone.
Also shown for both conditions is expression of the aP2 gene, used
as a positive control PPARγ target gene. Symbols represent the
mean± SEM for n = 4/agonist concentration.
binding of PPARγ was observed at the −1.1kb site, but only
transiently, at Day 4 (Figure 2). Observable but very modest
binding could be detected at the −8.4kb site and at Day 4
only (Figure 2). Since chromosome region-speciﬁc histone
acetylation is an important factor in promoting accessibility
of DNA to transcription factors, the magnitude of histone
acetylation at the PPARγ-binding sites was determined.
TherewashigherhistoneacetylationattheputativeDR1sites
of −1.1kb and −8.4kb with progression of adipogenesis, but
this was not apparent in the non-DR1 region (Figure 2)o r
at the putative DR1 site at −1.8kb that did not bind PPARγ
(data not shown).6 PPAR Research
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Acetylated
histone-4 (pan)
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Figure 2: Temporal Changes in Histone Modiﬁcations and PPARγ Binding at Putative DR1 Sites in the Promoter Region of the Murine
TUSC5 Gene During 3T3-L1 Adipocyte Diﬀerentiation. ChIP studies were performed in preadipocytes and maturing adipocytes at days
4a n d8d a y sp o s t d i ﬀerentiation initiation, employing anti-acetylated histone H3 (K9), anti-acetylated histone H4 (pan), or anti-PPARγ
antibodies and sequence-speciﬁc primers for putative DR1 sites (PPAR-response elements) located at promoter regions −8.4 and −1.1kb
relative to the murine TUSC5 start codon. Shown are images representative of 3 independent experiments.
Considering the robust induction of murine adipocyte
Tusc5 mRNA and protein levels by pharmacologic PPARγ
agonists in cell culture (Figure 1 and Supplementary Figure
1), we reasoned that if these were translatable to the clinical
setting, Tusc5 transcript and protein abundance would be
increasedinthesubcutaneousWATofhumantype2diabetic
volunteerstreatedwiththiazolidinediones(TZDs).However,
as shown in Figure 3, Tusc5 WAT transcript abundance did
not increase following ≥11-week pioglitazone treatment,
unlike the increases observed for the transcript levels of the
established PPARγ target genes PEPCK1 and LPL (P = .07
and P = .09, resp.). Notable was the large variability in
Tusc5geneexpressionchangesovertimebothintheplacebo-
and pioglitizone-treated subjects. Using a subset of patients
for whom archived WAT was available for measurement
of Tusc5 protein abundance, consistent with the mRNA
results there was large person-to-person variability in Tusc5
expression and no eﬀect of pioglitazone treatment on Tusc5
proteinlevelswhencomparingpre-andpost-treatmentWAT
(Supplementary Figure 2).
Microarray gene expression results from a separate
cohort of type 2 diabetics treated with pioglitizone for 12
weeks also showed no increased Tusc5 transcript levels in the
WAT when comparing pre- versus posttreatment matched
samples (in arbitrary ﬂuorescence signal units): 3084 ± 564
versus 3017 ± 601 in pre- versus posttreatment, respectively
(P>. 1). However, in subjects treated for the same period of
time but using rosiglitazone, there was a trend for increased
Tusc5 mRNA expression: 3132 ± 351 versus 4286 ± 433
(P = .07).
3.2. Negligible Eﬀects of PPARγ Agonism on Tusc5 Expression
outside the Context of Adipocytes. The basis for the unique
tissue speciﬁcity of Tusc5 expression remains unexplored,
but the robust activation of Tusc5 gene expression by PPARγ
agonists in murine adipocytes prompted us to consider
whether lack of expression in some tissues emanates from
limited endogenous PPARγ expression. To address this
question, we examined whether manipulation of PPARγ
expression in liver cells could trigger Tusc5 expression.
First, we opportunistically studied archived liver samples
derived from mice treated with adenoviruses containing
LacZ control overexpression constructs or viruses deliv-
ering PPARγ1, the main PPARγ in liver and most other
nonadipocytecells[12],orPPARγ2[13],theprimaryPPARγ
typeinfatcells.Asexpected,wedetectedamarkedinduction
of PPARγ mRNA expression in the livers of PPARγ1
or PPARγ2 adenovirus-treated mice relative to controls
(Figure 4, consistent with prior published reports using
these samples: [12, 13]), indicating successful delivery of the
transcriptionfactorstoliverinvivo.Wholeliverpreparations
can express trace amounts of mRNA for the PPARγ target
gene adiponectin (AdipoQ, probably from Kuppfer cells),
and following overexpression of either PPARγ isoform the
relative abundance of adiponectin was massively increased
in relative terms (Figure 4), as expected based on prior
reports using these liver samples [12, 13]. Notably, while
large in relative terms, the AdipoQ induction resulted in
mRNA abundance that remained <1% of that measured in a
sampleofmurineWATanalyzedinparallel(datanotshown).
In contrast, trace liver Tusc5 mRNA abundance was not
increased by overexpression of PPARγ1( Figure 4,l e f tp a n e l )
and was only modestly increased to 173 ± 17% of control
trace levels in PPARγ2-overexpressing mice (Figure 4,r i g h t
panel). Taken together, these results indicate that increased
PPARγ2a c t i v i t y ,b u tn o tP P A R γ1 activity, in mouse liver in
vivo can induce Tusc5 gene expression, but only to levels that
are a fraction of those typically determined in murine WAT
and two orders of magnitude less in relative terms to the
induction observed for AdipoQ.PPAR Research 7
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Figure 3: Subcutaneous WAT mRNA Expression for Tusc5 is
not Increased in Type 2 Diabetic Subjects Treated >11 Weeks
with Pioglitazone (PIO). Samples of subcutaneous WAT were
biopsied before and after treatment with placebo (n = 16: 7
male, 9 female) or PIO (n = 16: 5 male, 11 female) and relative
abundance of Tusc5 transcript was determined, using placebo
group baseline expression as comparator. No change was observed
in Tusc5 expression, in contrast to increases observed in mRNA
levels for phosphoenolpyruvate carboxykinase 1 (PEPCK1/Pck1)
and lipoprotein lipase (LPL) (†P = .07–.09). Values are means ±
SEM.
Second, in another set of studies addressing whether
Tusc5 expression can be induced in non-adipocytes overex-
pressing PPARγ, human HepG2 hepatoblastoma stable cell
lines containing Tet-oﬀ constructs (HepG2-tet-oﬀ-hPPAR
cells: PPAR isoforms α, β/δ, γ1, γ2) were examined under
conditions in which PPAR expression was induced, with or
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Figure 4: Experimental Overexpression of PPARγ1o rP P A R γ2
in Mouse Livers in vivo Increases Adiponectin Expression but
Fails to Strongly Increase Tusc5 mRNA Abundance. Mice were
treated with adenoviruses containing LacZ (controls) or expression
constructs to drive PPARγ1 (left bars, n = 3/group) or PPARγ2
(right bars, n = 6 & 7/group in controls and PPARγ2, resp.).
Either condition signiﬁcantly increased PPARγ mRNA levels and
adiponectin (AdipoQ) expression relative to LacZ controls (∗∗P<
.01; ∗∗∗P<. 001). Eﬀects on Tusc5 expression were either not
signiﬁcant (PPARγ1) or modest (PPARγ2; P<. 01). Means ± SEM
are depicted.
without treatment with speciﬁc ligands to trigger the PPAR
isoform activities. The conditions mimicked those described
previously that demonstrated successful induction of PPAR
target genes in this model [14]. Unlike positive control
human WAT cDNA analyzed in parallel, Tusc5 mRNA
was nondetectable in HepG2 cells under all conditions
(transcripts for leptin and AdipoQ/adiponectin were also
not detected). The lack of Tusc5 induction in HepG2 cells
contrasted with a variety of PPAR target genes that were
induced under conditions of PPAR activation (Table 1).
Of these, PEPCK1 and ADFP were induced strongly by
agonist treatment in all PPAR isoform-expressing cells.
ACOX1 and CPT1b were induced by PPARα agonism,
but interestingly ACOX1 was also signiﬁcantly increased
by PPARδ and PPARγ agonists in cells expressing those
transcription factors. CPT1b transcript levels, in contrast,
were not increased by PPARγ activation.
3.3. Lack of Association of Tusc5 Coding Sequence Polymor-
phisms and WAT Gene Expression in Human Obesity
Eﬀects of Human Obesity and WAT Depot Site on Tusc5
mRNA Expression. Matched subcutaneous (SC) and visceral8 PPAR Research
Table 1: Relative transcript abundances of PPAR target genes in HepG2 cells experimentally-expressing diﬀerent PPAR isoforms, in the
presence or absence of isoform-selective agonists.
PPAR isoform expressed‡ PPAR agonist treatment†
− +
Treatment eﬀect
∗P<. 05
∗∗P<. 01
∗∗∗P<. 001
PPARα
Tusc5, adiponectin (adipoQ), leptin (ob) n.d. n.d.
PEPCK1 (Pck1) 100 ±7% 401 ±54% ∗∗
ACOX1 100 ±5% 177 ±4% ∗∗∗
CPT1b 100 ±6% 154 ±14% ∗
ADFP 100 ±13% 560 ±41% ∗∗∗
PPARδ
Tusc5, adiponectin (adipoQ), leptin (ob) n.d. n.d.
PEPCK1 (Pck1) 100 ±16% 548 ±90% ∗∗
ACOX1 100 ±3% 236 ±13% ∗∗∗
CPT1b 100 ±4% 137 ±8% ∗
ADFP 100 ±4% 1830 ±153% ∗∗∗
PPARγ1
Tusc5, adiponectin (adipoQ), leptin (ob) n.d. n.d.
PEPCK1 (Pck1) 100 ±5% 336 ±31% ∗∗
ACOX1 100 ±7% 162 ±1% ∗∗
CPT1b 100 ±1% 114 ±12%
ADFP 100 ±11% 281 ±11% ∗∗∗
PPARγ2
Tusc5, adiponectin (adipoQ), leptin (ob) n.d. n.d.
PEPCK1 (Pck1) 100 ±3% 534 ±113% ∗
ACOX1 100 ±3% 172 ±22% ∗
CPT1b 100 ±9% 88 ±2%
ADFP 100 ±19% 278 ±64% P = .056
‡Using HepG2 Tet-oﬀ human PPAR isoform-speciﬁc overexpressing stable cell lines [14]( s e eM e t h o d s ) ;n = 3/treatment.
†PPAR isoform-selective agonists used for PPARα, δ, γ1, γ2 experiments were, respectively, GW7647 (1μM), GW501516 (100nM), and rosiglitazone (1μM);
cells were treated for 24 hours prior to mRNA collection.
n.d.: not detectable (note that Tusc5, adiponectin, and leptin transcripts were readily detected in a human WAT sample run in parallel).
(omental) adipose tissue mRNA samples from a cohort of
obese and nonobese French women, previously described in
an expression proﬁle study of adipose 11ß-hydroxysteroid
dehydrogenase[15]andsynuclein-γ [16],wereusedtodeter-
mine whether Tusc5 is diﬀerentially-expressed in human
obesity or across fat depots. Relative to non-obese SC WAT,
Tusc5mRNAabundancewas ∼20%reducedinobeseSCand
visceral WAT (Figure 5), but this modest eﬀect of obesity
was not statistically signiﬁcant. A signiﬁcant depot eﬀect
(P = .05) and depot × obesity interaction (P<. 001)
was observed, explained by the signiﬁcantly lower Tusc5
expression in the visceral versus SC WAT of non-obese
subjects that was not observed in obese persons (Figure 5).
TUSC5 Coding Variants in Obese and Lean Humans. We
sequenced TUSC5 exons and intron/exon boundaries in very
lean and very obese subjects to determine whether rare or
common coding variants are associated with diﬀerences in
human adiposity. Five missense and two sense mutations
were identiﬁed, but the genotype frequencies of each did
not diﬀer between lean and obese persons, and no nonsense
or frameshift mutations were detected (Table 2). Two rare
variants predict conserved amino acid sequences (V109V &
A167A). One rare missense mutation (A18T) that results
in substitution of uncharged, polar threonine for nonpolar
hydrophobic alanine had allele frequencies of 0.017 and
0.016 in obese and lean persons, respectively. Several other
relatively common missense mutations were observed: pro-
line to uncharged polar serine (P15S), serine to nonpolar
hydrophobic phenylalanine (S20F), and uncharged polar
glycine to serine (G57S). Finally, 6 lean and 3 obese subjects
were heterozygous carriers of a rare missense mutation
(I106T) that would result in a switch from nonpolar
hydrophobic isoleucine to threonine, and this sequence
variation is found in the highly conserved CD225 domain of
Tusc5(seeFigure 6).Theaminoacidchangesassociatedwith
these missense mutations are highlighted in a mammalianPPAR Research 9
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Figure 5: Adipose Tusc5 Transcript Levels are not Signiﬁcantly
Altered in Obese Adult Women. Samples from a cohort of obese
(n = 12) and non-obese (n = 10) women [15]w e r eu s e d
to assay mRNA abundance for Tusc5 by quantitative RT-PCR in
subcutaneous (SC) and visceral (omental) WAT. Means ± SEM
are depicted, with non-obese SC mRNA levels considered 100%.
There were no signiﬁcant eﬀects of obesity, but depot (P = .05)
and depot x obesity interaction (P<. 0001) were observed due
to the signiﬁcantly lower Tusc5 expression in the visceral versus
subcutaneous WAT of nonobese volunteers (∗∗P<. 01).
Tusc5 alignment (Figure 6) and notably the S20F and G57S
variants identiﬁed above were also observed in the human
Tusc5 GenBank protein sequence entries.
4. Discussion
Tusc5 displays an interesting biology, in that it is robustly
coexpressed in both adipocytes and peripheral aﬀerent
neurons, but its function has remained elusive and very
little is known about the molecular regulation of Tusc5
gene expression. Findings to date indicate that cold ambient
temperature markedly reduces rodent WAT and BAT Tusc5
mRNA levels, and Tusc5 expression rises during adipoge-
nesis in white and brown adipocytes [2, 4, 5]. The cold-
suppression of Tusc5 expression does not appear to be via
activation of β3-adrenergic receptors [5]. Up regulation of
Tusc5geneexpressionbyasingleconcentrationofthePPARγ
agonistGW1929inimmatureandmature3T3-L1adipocytes
[2] led us to assess whether murine TUSC5 gene is a bona
ﬁde PPARγ target gene. PPARγ targets speciﬁcally or highly
expressed in adipocytes are typically implicated in pathways
important to metabolic regulation, so characterizing the
biology of Tusc5 and its association with PPARγ should
further illuminate its role in metabolism and adipose tissue
function.
Results herein conﬁrm that the murine TUSC5 gene
is a PPARγ target in adipocytes and highlight that the
interrelationship between the TUSC5 gene and PPARγ is
Table 2: Frequencies of rare and common coding variants in
TUSC5 in lean and obese subjects.
Amino acid change
(nucleotide shift)
Allele frequency
Lean Obese
P15S
(C→T)
CC=317 CC=318
CT=58 CT=61
TT=2 TT=2
A18T
(G→A)
GG=365 GG=368
AG=12 AG=12
AA=0 AA=1
S20F
(C→T)
CC=180 CC=197
CT=172 CT=151
TT=25 TT=33
G57S
(G→A)
GG=210 GG=217
AG=146 AG=139
AA=21 AA=25
I106T
(T→C)
TT=371 TT=378
CT=6 CT=3
CC=0 CC=0
V109V
(C→T)
CC=376 CC=381
CT=1 CT=0
TT=0 TT=0
A167A
(C→T)
CC=160 CC=375
CT=0 CT=1
TT=0 TT=0
quite complex. First, dose-response experiments in 3T3-
L1 adipocytes using a TZD PPARγ agonist (troglitazone)
and a non-TZD agonist (GW1929) resulted in signiﬁcantly
increased Tusc5 mRNA abundance, with EC50 diﬀerences
that matched the known potencies of these compounds
for the PPARγ receptor (see [6]). This suggests that up-
regulation of Tusc5 expression by these compounds is not
due to oﬀ-target eﬀects and is not agonist class speciﬁc.
Second,chromatinimmunoprecipitation studiesprovedthat
endogenous murine PPARγ directly binds one predicted
TUSC5 DR1 site strongly (a −1.1kb PPAR-response ele-
ment) and another weakly (−8.4kb site) during 3T3-L1 adi-
pogenesis. While these results establish that interactions take
place between PPARγ a n dt h em u r i n eT U S C 5g e n ei n3 T 3 -
L1 adipocytes, PPARγ binding to murine TUSC5 promoter
elementswastransient(Figure 2)andonlydetectedatamid-
stage of adipocyte maturation (Day 4 post-diﬀerentiation)
but not in more mature fat cells (Day 8). The basis for this
is not known, but time-dependent shifts in concentrations of
endogenous ligands and/or changes in activators/repressors
of PPARγ DNA binding are likely explanations. There is
precedent for the latter. Activity of PPARγ at the LPL gene
promoter is attenuated upon complex formation of ligand-
bound PPARγ to hypophosphorylated retinoblastoma pro-
tein (RB) and histone deacetylase 3 (HDAC3) [18]. This
inhibitory complex is adipogenesis stage-dependent, such
that earlier in adipogenesis (i.e., at Day 4), hyperphospho-
rylation of RB minimizes complex formation (thus enabling10 PPAR Research
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Figure 6: Locations of Single-Nucleotide Polymorphisms (SNPs) Impacting the Coding Region of Human TUSC5. A number of SNPs were
detected in the course of resequencing the TUSC5 open reading frame of >700 human subjects (see Table 2), with 5 SNPs encoding amino
acid changes (see diamonds; residue changes are noted). Notably, the I106T shift is within the CD225 domain of Tusc5 (domain bordered
by arrows), and the P15S change is at a site highly-conserved across species. The alignment tool in VectorNTI (Invitrogen) was used to
compare known and putative Tusc5 GenBank sequences from two human entries (BAC43751 [HUMAN-A] and NP 758955 [HUMAN-B]),
chimpanzees (XP 001153397), mice (NP 808377), rats (NP 001034252), dogs (XP 548306), and cattle (XP 605998).
maximal PPARγ activity at the LPL promoter), but later
in adipogenesis (at Day 8) PPARγ-RB-HDAC3 complex
formation is more apparent [18]. Nevertheless, expression of
LPL remains robust in fully developed adipocytes [2, 18, 19],
indicating that other factors sustain LPL expression in the
face of reduced PPARγ binding to the LPL promoter later in
adipogenesis. It remains to be established in future studies
whether the PPARγ-RB-HDAC3 interaction plays a role in
temporal regulation of the TUSC5 gene locus in maturing
fat cells.
There is some support for the idea that additional
DR1 sites participate in driving net Tusc5 gene expression.
Coupling ChIP with whole genome tiling arrays (ChIP-
chip approach) in fully mature, 10 day postdiﬀerentiated
3T3-L1 adipocytes, Lazar and colleagues identiﬁed three 3 
UTR PPARγ binding sites on the murine TUSC5 gene (see
PPAR 4579, PPAR 4580, and PPAR 4581 of Supplementary
Table 1 in [20]). These investigators did not observe PPARγ
binding to the −1.1kb DR1 site, not unexpected considering
our results showing that binding drops oﬀ after 4 days of
adipogenesis. An additional site within the ﬁrst intron of
TUSC5 was also observed upon further examination of the
raw ChIP-chip data (Lefterova and Lazar, personal com-
munication), and intronic PPARγ associations can clearlyPPAR Research 11
inﬂuence gene expression (i.e., for retinol saturase, [21]).
Thus, additional research employing a variety of TUSC5
promoter-intronic-luciferase constructs with or without
PPARγ ligand treatment will be required to help unravel how
thesePPARγbindingsitesinisolationorincombinationalter
gene expression.
The complicated relationship between PPARγ and Tusc5
was further highlighted by opportunistic analysis of archived
WAT samples from clinical studies of type 2 diabetics treated
for >11 weeks with the PPARγ agonist pioglitazone [8], in
which we did not detect an increase in WAT Tusc5 mRNA by
quantitative PCR or protein despite increases in expression
of other target genes (Figure 3). Microarray adipose tissue
expression data from a diﬀerent human TZD study in type 2
diabetics conﬁrmed the observation above that pioglitazone
treatment does not increase Tusc5 mRNA levels. In contrast,
rosiglitazone tended to increase Tusc5 mRNA levels, but this
was highly variable among the individuals tested. This latter
observation may be due to ligand-selective gene regulation
(i.e., [22]) that is explained by the selective PPAR modulator
(SPPARM) model [23]. Under this model, ligand-bound
PPARγ molecules can assume ligand-speciﬁc 3-dimensional
structures that confer ligand-speciﬁc transcriptional activity
through diﬀerential cofactor interaction and DNA binding-
speciﬁcity. The lack of eﬀect of PIO in triggering WAT Tusc5
expression in our human cohorts (in contrast to the robust
increase in murine adipocytes) might point to potential
species-speciﬁc diﬀerences in the Tusc5-PPARγ association,
or large variability in this association across individuals
diﬀering in metabolic status or disease severity. Finally,
considering that samples were obtained only at a single late
timepoint following pioglitazone treatment, it is possible
that WAT Tusc5 expression was actively regulated during the
more dynamic phase of early TZD treatment.
Several PPARγ target genes, including the adipocyte
marker adiponectin, can be induced in non-adipocytes by
experimental overexpression of PPARγ, indicating that the
latter is suﬃcient for activation of “adipocyte-speciﬁc” gene
expression outside the context of fat tissue. For example,
adenoviral delivery of PPARγ1 in mouse liver markedly
increased adiponectin mRNA levels and increased liver fat
accumulation[12].Similarly,adenoviralinjectionofPPARγ2
in mice resulted in a lipogenic liver phenotype and induction
of several PPARγ target genes [13]. We reasoned that Tusc5
expression, like that of the classic PPARγ target adiponectin,
should be up-regulated by expressing PPARγ isoforms in
liver. However, liver Tusc5 mRNA changes following hep-
atic PPARγ overexpression in vivo were nominal at best,
especially when compared to a massive relative increase in
adiponectin mRNA levels. Expression of Tusc5 could not
be induced in the human hepatocyte cell line HepG2 even
after maneuvers that increased PPAR activity and hence
expression of assorted PPAR target genes (Table 2; also see
[14]). These results indicate that in contrast to adiponectin
and some other PPARγ target genes, factors present in
adipocytes but lacking in liver are required for induction
of the Tusc5 gene by endogenous or pharmacologic PPARγ
agonists. A non-adipocyte cell type that strongly expresses
Tusc5 is the peripheral aﬀerent neuron, so it will be
interesting to determine if Tusc5 expression can be increased
by PPARγ agonists in these cells.
Similar to the pattern observed for other genes that mark
the adipocyte maturation process (adiponectin, ADD1, aP2,
e.g.) [24], we have demonstrated that early in adipogenesis
histone acetylation at Tusc5 PPARγ binding sites increases.
Such site-speciﬁc chromosomal modiﬁcations are associated
with access for gene regulatory factors including PPARγ,b e s t
exempliﬁed by cyclin D1 inhibition of PPARγ binding to
LPL and aP2 DR1 sites via HDAC recruitment and reduced
histoneH3acetylation[25,26].Increasedhistoneacetylation
in adipocyte genes is due in part to marked down-regulation
of histone deacetylase (HDAC) enzyme levels and reduced
interaction of HDACs with mature adipocyte marker gene
loci several days following induction of 3T3-L1 adipocyte
diﬀerentiation [24]. It is notable that the transition from
limited Tusc5 gene histone acetylation in preadipocytes to
increased acetylation by at least 4 days following the start
of adipocyte diﬀerentiation is consistent with the induction
kinetics of Tusc5 gene expression in this cell model [2].
Therefore, these results are consistent with the hypothesis
that Tusc5 expression, like other genes triggered during
the adipogenesis program, is regulated through increased
histone acetylation at PPARγ chromosomal binding sites
within the murine Tusc5 gene. Interestingly, PPARγ binding
to the Tusc5 promoter was transient despite maintenance
of histone acetylation at the DR1 sites throughout 3T3-
L1 adipocyte maturation, suggesting that acetylation and
hence concomitant transcription factor accessibility to these
sites does not alone explain temporal changes in PPARγ
binding.
Despite emerging evidence for a role for Tusc5 in
adipocyte function, robust WAT expression of the gene, and
its regulation by PPARγ agonists in cultured adipocytes, it
is not known if Tusc5 expression or activity is associated
withobesityphenotypes.Onlyoneotherstudyhasaddressed
this question, using Zucker fatty rats that lack proper
leptin signaling and therefore become extremely obese:
Tusc5 mRNA and protein levels were very slightly increased
in subcutaneous WAT, unchanged in mesenteric, and yet
decreased substantially in epididymal WAT [4]. We observed
no signiﬁcant diﬀerence between adult obese and non-obese
women in terms of WAT Tusc5 transcript levels (Figure 5).
The frequencies of TUSC5 coding sequence variants in 758
lean and obese volunteers determined if rare or common
variantsareassociatedwithbodycompositionphenotypesin
the human population. Several SNPs were identiﬁed, but the
frequencies of these were not diﬀerent when comparing lean
and obese subjects (see Table 2). Mutations leading to altered
amino acid residues conserved across mammalian Tusc5
orthologues (or in the CD225 domain) are predicted to lead
tophysiologically-importantproteinfunctionalchanges,and
notably an I106T shift in a highly-conserved portion of
the CD225 domain was detected and introduces a charged
residue at that site (Figure 6). The functional implications
for this remain to be evaluated. Thus, our results do not
support the hypothesis that WAT gene expression diﬀerences
or coding polymorphisms in TUSC5 are associated with lean
or obese phenotypes.12 PPAR Research
In conclusion, these experiments have established that
the murine TUSC5 gene is a PPARγ-regulated locus in
adipocytes, but whether this association occurs in human
fat cells remains to be established. The PPARγ-TUSC5
interaction is highly-complex, temporally-regulated during
adipogenesis, and involves tissue speciﬁc factors driving
expression of the gene in adipocytes in response to exper-
imental PPARγ agonism. There is little evidence for a
major role for Tusc5 WAT expression diﬀerences in obesity
development, and although we identiﬁed several missense
mutations in the TUSC5 gene locus, none was associated
with adiposity in a large human cohort. Therefore, it appears
that future studies of Tusc5 biology should focus less on
the association of the protein with adipose tissue abundance
phenotypes and more on its participation in other facets of
adipocyte function.
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